TY  - GEN
AB  - Successful cancer treatment continues to elude modern medicine and its arsenal of therapeutic strategies. Therapy resistance is driven by tumor heterogeneity, complex interactions between malignant, microenvironmental and immune cells and signaling pathway cross talk. With the ultimate goal of improved molecularly targeted therapeutic efficacy, we have developed and optimized a fluorescence imaging platform termed TRIPODD (Therapeutic Response Imaging through Proteomic and Optical Drug Distribution), resulting in the only methodology capable of simultaneous quantification of single-cell drug target availability and protein expression with preserved spatial context within a tumor. TRIPODD will enable an improved mechanistic understanding of clinically-relevant treatment regimens through spatially resolved single-cell quantification of drug concentration and proteomic response to identify mechanisms of resistant subclonal population outgrowths driving therapeutic resistance.
AU  - McMahon, Nathan P.
DA  - 2021
DO  - 10.6083/vh53ww43g
DO  - DOI
ID  - 9292
KW  - Proteomics
KW  - High-Throughput Nucleotide Sequencing
KW  - Fluorescent Antibody Technique
KW  - drug therapeutic index
KW  - fluorescence imaging
L1  - https://digitalcollections.ohsu.edu/record/9292/files/McMahon.Nathan.2021.pdf
L2  - https://digitalcollections.ohsu.edu/record/9292/files/McMahon.Nathan.2021.pdf
L4  - https://digitalcollections.ohsu.edu/record/9292/files/McMahon.Nathan.2021.pdf
LK  - https://digitalcollections.ohsu.edu/record/9292/files/McMahon.Nathan.2021.pdf
N2  - Successful cancer treatment continues to elude modern medicine and its arsenal of therapeutic strategies. Therapy resistance is driven by tumor heterogeneity, complex interactions between malignant, microenvironmental and immune cells and signaling pathway cross talk. With the ultimate goal of improved molecularly targeted therapeutic efficacy, we have developed and optimized a fluorescence imaging platform termed TRIPODD (Therapeutic Response Imaging through Proteomic and Optical Drug Distribution), resulting in the only methodology capable of simultaneous quantification of single-cell drug target availability and protein expression with preserved spatial context within a tumor. TRIPODD will enable an improved mechanistic understanding of clinically-relevant treatment regimens through spatially resolved single-cell quantification of drug concentration and proteomic response to identify mechanisms of resistant subclonal population outgrowths driving therapeutic resistance.
PB  - Oregon Health and Science University
PY  - 2021
T1  - In situ therapeutic response imaging using a novel fluorescence imaging platform - TRIPODD
TI  - In situ therapeutic response imaging using a novel fluorescence imaging platform - TRIPODD
UR  - https://digitalcollections.ohsu.edu/record/9292/files/McMahon.Nathan.2021.pdf
Y1  - 2021
ER  -